ArticleOpen forum infectious diseases2026
Risk Factors and Outcomes of Disseminated Nocardiosis Across Host Risk Groups.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Risk factors for mortality after nocardiosis in Southern France (2014-2024).IJID regions · 2026Article
- Imaging characteristics, yield of computed tomography, and clinical outcomes of central nervous system nocardiosis.Infection · 2026Article
- Pulmonary Nocardiosis Diagnosed by Plasma Metagenomic Next-Generation Sequencing in a Patient With Recurrent Febrile Neutropenia.Case reports in infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nocardiosis primarily affects immunocompromised hosts and those with chronic pulmonary disease but can also occur in immunocompetent patients. Predictors of dissemination and its role in long-term mortality remain unclear. Methods: We conducted a retrospective cohort study of adults with nocardiosis diagnosed from January 1, 2010 to December 31, 2023. Patients were categorized into 3 groups: immunocompromised, immunocompetent with chronic lung disease, and immunocompetent without chronic lung disease. We evaluated risk factors associated with dissemination at the time of diagnosis and predictors of 1-year mortality. Multivariable logistic regression identified risk factors for dissemination. Cox regression assessed predictors of 1-year mortality. Results: Among 232 patients, 44 (19.0%) had disseminated infection and 36 (15.5%) died within 1-year. Dissemination was more common among patients who were immunocompromised (odds ratio ([OR] 6.26, 95% confidence interval [CI] 2.26-20.53) or immunocompetent without chronic lung disease (OR 5.09, 95% CI 1.75-17.15). Lymphopenia and infection with Conclusions: Immunocompromised patients and those without chronic lung disease are at increased risk for disseminated nocardiosis. While dissemination alone is not predictive of 1-year mortality overall, it is directly associated with mortality among immunocompetent patients with chronic lung disease. These findings highlight the need for tailored prognostic assessment and management in this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.